Moderna, Inc. (MRNA) stock is experiencing a significant surge, soaring 9.39% in Thursday's intraday trading session. This remarkable uptick comes on the heels of reports suggesting that the biotech company is in discussions about a potential buyout.

According to STAT News, Moderna is reportedly in talks with at least one large pharmaceutical company regarding a deal of substantial scope, which could include a complete buyout. This news has sparked investor interest, driving the stock price higher as market participants speculate on the potential for a lucrative acquisition.

While details of the potential deal remain undisclosed, the mere possibility of a buyout has injected renewed enthusiasm into Moderna's stock. The company, known for its mRNA technology and COVID-19 vaccine, has been facing challenges in the post-pandemic market. A potential acquisition by a larger drugmaker could provide Moderna with additional resources and market reach, potentially enhancing its long-term prospects in the competitive pharmaceutical industry.